Advertisement

Topics

Parvus grants Genentech rights to autoimmune drug

05:47 EDT 17 May 2019 | SmartBrief

Genentech has acquired rights to develop and market Parvus Therapeutics' Navacim nanoparticle therapeutics for the treatment  -More

Original Article: Parvus grants Genentech rights to autoimmune drug

NEXT ARTICLE

More From BioPortfolio on "Parvus grants Genentech rights to autoimmune drug"

Advertisement
Quick Search
Advertisement
Advertisement